March 2017: Prof. William Gallagher Awarded Prestigious Medal for Outstanding Contribution to Irish Cancer Research
Congratulations to Professor William Gallagher, who was the inaugural recipient of the Irish Association of Cancer Research (IACR) Cancer Research Medal at the annual IACR Conference held in Kilkenny on 22nd-24th February 2017. This prestigious award recognises his outstanding contribution to the cancer research community in Ireland throughout his career.
Professor Gallagher, a Professor of Cancer Biology at University College Dublin, is the co-founder and Chief Scientific Officer of OncoMark and Director of the UCD Conway Institute and of BREAST-PREDICT, the Irish Cancer Society's first Collaborative Cancer Research Centre.
Presenting the award on the night was Professor William Watson, President of the IACR, who described the outstanding contribution of Professor Gallagher to the Irish cancer research community over the years. Highlighted in particular was his early understanding of the importance of commercialisation of research outputs, and protection of intellectual property, when research and development activities in Ireland were still in their infancy.
Accepting his award, Professor Gallagher thanked his peers and mentors, and gave his perspective on the cancer research ecosystem in Ireland, in his talk 'Cancer (Research) in Ireland: Past, Present and Future'. He described the past contributions of unsung heroes of Irish cancer research, such as Dr. Denis Burkitt, who first described Burkitt's Lymphoma, and Dr. Mary Cole, who co-authored the first clinical study on the use of tamoxifen in treating breast cancer patients, in 1971. He went on to highlight the exceptional quality of cancer research ongoing in Ireland today, with high-impact publications, increasing rates of participation in clinical trials and excellent training programmes in place for up-and-coming researchers.
Professor Gallagher is the co-founder and Chief Scientific Officer of OncoMark. OncoMark is focused on the development and application of biomarker panels for cancer, primarily aimed at identifying risk of recurrence. In 2016, the company was awarded €2.75 million from the EU Horizon 2020 SME Instrument programme to clinically validate a prognostic test for breast cancer, called OncoMasTR, which is based on a panel of genetic 'drivers' of breast cancer. OncoMark recently secured a further €2.1 million in investment to support the commercial development of this assay, with plans to launch this assay in 2018.